Cost of Revenue Comparison: Exelixis, Inc. vs Viridian Therapeutics, Inc.

A Decade of Cost Dynamics: Exelixis, Inc. vs Viridian Therapeutics, Inc.

In the ever-evolving landscape of biotechnology, understanding cost structures is pivotal. Over the past decade, Exelixis, Inc. and Viridian Therapeutics, Inc. have showcased contrasting trajectories in their cost of revenue. Exelixis, Inc. has seen a remarkable increase, with costs surging by over 3,400% from 2014 to 2023. This growth reflects their expanding operations and market presence. In contrast, Viridian Therapeutics, Inc. experienced a more volatile journey, peaking in 2019 with a cost of revenue nearly 10 times higher than in 2014, before plummeting to a mere fraction of that in 2021. This fluctuation highlights the challenges and strategic shifts within the company. As of 2023, Exelixis, Inc.'s cost of revenue is approximately 55 times that of Viridian, underscoring their differing scales and operational strategies. These insights offer a window into the financial health and strategic priorities of these biotech players.